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Although combined pulmonary fibrosis and emphysema (CPFE) might be relevant to lung can-
cer, no comparison studies have been done. We evaluated the risk of lung cancer among CPFE
patients compared to IPF and emphysema patients.
We retrospectively reviewed the medical records of patients who were diagnosed as CPFE,
IPF and emphysema using chest CT scans at Seoul National University Hospital from Jan 2000 to
Dec 2011. Patients with CPFE were enrolled and matched (1:1:2) with IPF and emphysema pa-
tients based on the radiological criteria. The main outcome was time to diagnosis of lung can-
cer and evaluated with Cox-proportional hazard regression.
Forty-eight CPFE, 48 IPF, and 96 emphysema patients were included in this study. Twenty-
five cases of lung cancer occurred. The CPFE group had a higher risk of lung cancer (adjusted
HR 4.62, 95% CI 1.58e13.55) than that of the emphysema group. Also, IPF group had a higher
risk of lung cancer (adjusted HR 4.15, 95% CI 1.03e16.78) than that of emphysema group. How-
ever, there was no statistically significant difference in lung cancer risk between the CPFE and
IPF group. Additionally, the CPFE group had a higher risk of lung cancer or death (adjusted HR
4.62, 95% CI 2.25e9.47) than that of the emphysema group.ulmonary and Critical Care Medicine, Department of Internal Medicine and Lung Institute of Medical
rsity College of Medicine, Seoul National University Hospital, 101 Daehak-Ro, Jongno-Gu, Seoul 110-
072 4743; fax: þ82 2 762 9662.
.com, kauri670@gmail.com (C.-H. Lee).
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Lung cancer risk among patients with CPFE 525In conclusion, patients with CPFE and IPF had a higher risk of lung cancer than those with
emphysema, although lung cancer risk was similar between CPFE and IPF.
ª 2014 Elsevier Ltd. All rights reserved.Introduction
Since the 1990s, the coexistence of pulmonary fibrosis and
emphysema in HRCT has been reported [1]. Cottin et al. [2]
defined combined pulmonary fibrosis and emphysema
(CPFE) as a disease entity characterized by upper lung
predominant emphysema and lower lung predominant
fibrosis. CPFE is predominant among male smokers and
characterized by a relatively preserved lung volume and
decreased diffusing capacity [2].
Several studies have evaluated the clinical course and
complications of CPFE. Mejia et al. reported the worse
survival of CPFE patients compared to those with IPF only,
and pulmonary hypertension was an independent predictor
of mortality [3]. In our previous study, CPFE patients
showed poorer survival than that of the emphysema only
group [4]. Also it is reported that CPFE was associated with
a slower decline in FVC and DLco over time than that in the
IPF only group [5]. However, the association between CPFE
and lung cancer has not been fully evaluated, although
there have been some descriptive studies. These studies
reported a high prevalence of lung cancer in CPFE patients
[6], and vice versa, a high prevalence of CPFE compared to
IPF in lung cancer patients [7].
Emphysema and IPF have been regarded as indepen-
dent risk factors for lung cancer development, respec-
tively [8e10]. In addition, smoking, which is more strongly
associated with CPFE patients [11], is the most important
risk factor for lung cancer [12]. Therefore, we hypothe-
sized that CPFE is a higher risk factor for the development
of lung cancer. To test this hypothesis, we attempted to
compare the risk for lung cancer development among
patients with CPFE, with IPF only, and with emphysema
only.
Methods
Patients
All chest CT scans that were performed at Seoul National
University Hospital from Jan 2000 to Dec 2011 were evalu-
ated and patients who had the terms ‘diffuse, centrilobular
emphysema’, ‘IPF’, ‘UIP’, ‘honeycombing’ or ‘CPFE’ in the
final CT report were screened. Among the screened pa-
tients, firstly we included patients with CPFE (CPFE group)
based on the diagnostic criteria described below. Then
each CPFE patients was individually matched according to
age (3 years), sex, and initial date (6 months) of the
diagnosis with 1:1:2 ratio (one CPFE patient: one IPF only
patient: two emphysema only patients). Patients with IPF
only (IPF group) and those with emphysema only (emphy-
sema group) were selected randomly from screened pa-
tients and were included if they met the diagnostic criteria
described below.Diagnostic criteria of CPFE, IPF and emphysema was
based on radiologic findings on chest CT scans. IPF was
diagnosed with the criteria for the UIP pattern as in ‘An
official ATS/ERS/JRS/ALAT statement: idiopathic pulmo-
nary fibrosis: evidence-based guidelines for diagnosis and
management’ [13] as follows: subpleural, basal predomi-
nant reticular abnormality or honeycombing with or
without traction bronchiectasis and the absence of an
inconsistent UIP pattern. Emphysema was diagnosed when
the extent of low attenuation area with less than
950 Hounsfield unit involved more than 10% of the lung
parenchyme at chest CT scans. Patients who met both the
criteria for IPF and emphysema were categorized into the
CPFE group [14]. Patients who had any malignancy including
lung cancer at the time of the initial diagnosis, patients
with connective tissue diseases, and patients with other
parenchymal lung diseases, such as drug-associated inter-
stitial lung disease, hypersensitivity pneumonitis, sarcoid-
osis, eosinophilic pneumonia and a lung destroyed by
tuberculosis were excluded.
All CT scans of these patients were reviewed by two
radiologists and one pulmonologist and a diagnosis of CPFE,
IPF or emphysema required a consensus among all the
reviewers. This study was approved by the Institutional
Review Board of Seoul National University Hospital (IRB No.
H-1207-011-415).Outcome and variables to measure
The main outcome was the time to the diagnosis of lung
cancer. The time to diagnosis was obtained using the
duration between the entry date and the index date. The
entry date was defined as the date when the patients were
diagnosed as CPFE, IPF or emphysema using chest CT scans
during the study period. The index date was defined as the
date of lung cancer diagnosis or the date of the last follow-
up during the study period among patients without lung
cancer. The time to diagnosis of lung cancer or death was
also obtained using the duration between the entry date
and the index date. In this case, the index date was defined
as the date of lung cancer diagnosis or the date of death
during the study period. The index date of survived patients
without lung cancer was 31 Aug 2013. Death registration
data was provided with the aid of Ministry of Security and
Public Administration.
All lung cancer cases were confirmed pathologically.
Histological type and clinical staging of lung cancers were
reviewed. Clinical staging was measured according to the
American Joint Committee on Cancer staging 7th [15]. Lo-
cations of the cancer were also reviewed and categorized
into three groups by location of the primary mass. When the
distance between the primary mass and visceral pleura was
less than 1 cm, we determined that these cancers were
located at the ‘subpleural’ area. However, when the
526 N. Kwak et al.distance was greater than 1 cm, these cancers were
determined to be located at the ‘non-subpleural’ area. The
distinction between the subpleural and non-subpleural area
was based on previous studies [16e18]. When several
masses were discovered and their distribution was diverse,
the location of these cancers was considered to be ‘not
differentiated’.
We reviewed the demographical characteristics and
spirometric results. Smoking status was categorized into
three groups and the cut-off period that determined cur-
rent and former smoking was six months. Spirometric re-
sults (FEV1/FVC(%), FEV1(%), and FVC(%)) that were taken
at the closest date from the entry date were analyzed.
Analysis
The clinical data of the patients are described as the mean
and standard deviation (SD). Chi-square tests and Fisher’s
exact tests were used for comparison of categorical vari-
ables, and the analysis of variance (ANOVA) and Krus-
kaleWallis tests were used for comparison of continuous
variables among the CPFE, IPF and emphysema groups.
KaplaneMeier analysis with log-rank test and multivariable
Cox-proportional hazard regression was performed to
analyze the main outcome. The durations between the
entry date and the index date, which were described
above, were used in the survival analysis. Variables with p-
value < 0.15 in the univariable analysis were used in the
multivariable Cox model to identify independent risk fac-
tors for lung cancer. We also performed the secondary
analysis to identify risk factors for lung cancer development
or death, in which the index dates were defined as the date
of lung cancer diagnosis or the date of death. A p-
value < 0.05 was regarded statistically significant. All sta-
tistical analyses were done with Stata 12.1 (StataCorp,
College Station, Texas, US).
Results
By screening the CT scan reports, 12,875 cases were
searched and 808 cases with CPFE, IPF and emphysema (71
patients with CPFE, 249 patients with IPF and 488 patientsTable 1 Baseline characteristics among CPFE, IPF and emphyse
CPFE (n Z 48)
Age, years, mean  SD 66.6  7.8
BMI, kg/m2, mean  SD 23.4  2.9
Follow-up duration, years, mean  SD 5.8  3.1
No. of admission, n, mean  SD 0.7  0.9
Smoking Status, n (%) n Z 46
Never 0 (0)
Former 23 (50.0)
Current 23 (50.0)
Pack-years, mean  SD 43.2  15.1
FEV1, %, mean  SD 95.0  15.7
FVC, %, mean  SD 91.4  15.1
FEV1/FVC, %, mean  SD 75.7  15.6
SD; standard deviation, BMI; body mass index, FEV1; forced expiratorwith emphysema) were sorted out. Forty-eight patients
were selected as CPFE group from 71 patients with CPFE.
Nine patients were excluded according to the exclusion
criteria mentioned above (Initial malignancy: 4,
amiodarone-induced pneumonitis: 1, connective tissue
disease: 2, destroyed lung by tuberculosis: 2). Individual
matching for age, sex and initial diagnosis date failed for 14
patients with CPFE (For example, there were no matched
female patients with emphysema). Finally, 48 patients with
CPFE were included for analysis. Then, forty-eight patents
with IPF and 96 patients with emphysema matched for age,
sex and the initial diagnosis date were selected.
Most patients were elderly and female patients were
excluded in the process of patient matching. Most patients
with CPFE and emphysema were smokers. IPF patients had
higher BMIs. Spirometry results revealed differences among
the three groups. The CPFE group had higher FEV1s than
that of the emphysema group and higher FVCs than that of
the IPF group. The mean FEV1/FVC among the CPFE pa-
tients was 75.7% (Table 1).
Twenty-five cases of lung cancer (12 in the CPFE group, 5
in the IPF group and 8 in the emphysema group) occurred
and 18 patients with lung cancer (3 in the CPFE group, 13 in
the IPF group and 2 in the emphysema group) died during
the follow-up period. 49 patients without lung cancer (13 in
the CPFE group, 24 in the IPF group and 12 in the emphy-
sema group) also died during the same period. The crude
incidence rates of lung cancer were 24.1 cases/103 person-
years, 23.1 cases/103 person-years, and 12.7 case/103 per-
son-years, respectively. In all the groups, NSCLC was more
common and squamous cell carcinoma was the most
frequent type of lung cancer (Table 2).
There was a statistically significant difference in loca-
tion of the primary mass among the three groups. Lung
cancer of the CPFE and IPF group was predominantly
located subpleurally. However, only one case of lung cancer
(12.5%) in the emphysema group was located in the sub-
pleural area.
In the KaplaneMeier analysis (Fig. 1) the log-rank test
showed the CPFE group had a higher risk of lung cancer
(p Z 0.018). Multivariable Cox-proportional hazard
regression analysis showed the CPFE group had higher
risk factor for cancer development compared to thema group.
IPF (n Z 48) Emphysema (n Z 96) p-Value
66.7  8.0 66.2  8.5 0.910
24.0  2.9 21.7  2.9 <0.001
4.5  2.9 6.6  3.0 0.001
0.9  1.5 0.6  1.5 0.064
n Z 47 n Z 92 <0.001
11 (23.4) 2 (2.1)
30 (63.8) 56 (60.9)
6 (12.8) 34 (37.0)
21.2  20.4 44.5  20.4 <0.001
93.4  21.0 73.4  25.1 <0.001
80.1  17.7 94.5  20.4 <0.001
79.4  15.2 53.8  16.9 <0.001
y volume in 1 s, FVC; forced vital capacity.
Table 2 The characteristics of lung cancer among the
CPFE, IPF and emphysema group.
CPFE IPF only Emphysema
only
p-Value
The number of lung
cancer
development
12 5 8
Crude incidence
(per 103
persons-year)
24.1 23.1 12.7
Histology, n 0.690
Squamous cell 5 3 5
Adenocarcinoma 1 0 2
Poorly
differentiated
3 1 0
Small cell
carcinoma
3 1 1
Clinical stage
of NSCLC, n
0.717
I 2 2 1
II 1 0 0
III 4 1 2
IV 2 1 4
Clinical stage
of SCLC, n
Limited disease 1 1 0 1.000
Extensive
disease
2 0 1
Location of
primary mass
0.003
Subpleural 8 5 1
Non-subpleural 1 0 6
Not differentiated 3 0 1
NSCLC; non-small cell lung cancer, SLCC; small cell lung cancer.
Lung cancer risk among patients with CPFE 527emphysema group. After adjusting for confounding factors
(age, pack-years and FEV1(%)), the CPFE group had a higher
risk factor for lung cancer development compared to the
emphysema group (adjusted HR (aHR), 4.62, 95%Figure 1 KaplaneMeier estimates of time to lung cancer
among patients with CPFE, IPF and emphysema.confidence interval (CI) 1.58e13.55, p Z 0.005). Also, the
IPF group had a higher risk factor for lung cancer devel-
opment compared to the emphysema group (aHR 4.15, 95%
CI 1.03e16.78, p Z 0.046). However, there was no signifi-
cant difference in lung cancer development between the
CPFE and IPF group (aHR 1.11, 95% CI 0.38e3.28, pZ 0.845)
(Table 3).
We also calculated the risk for lung cancer or death.
After adjusting for confounding factors (age, pack-years,
FEV1/FVC (%) and FVC (%)), the CPFE group had a higher risk
factor for lung cancer or death compared to the emphysema
group (aHR 4.62, 95% CI 2.25e9.47, p < 0.001) (Fig. 2 and
Table 4).Discussion
This is the first comparison study evaluating the risk of lung
cancer in CPFE. We showed that patients with CPFE had a
higher risk of lung cancer development than that of pa-
tients with emphysema only. Compared to those with IPF,
we did not find a statistically significant higher risk of lung
cancer among patients with CPFE.
Lung cancer is the leading cause of cancer-related death
in Korea [19]. In 2008, lung cancer was ranked fourth for
the incidence rate but listed as the most fatal cancer. This
explains 21.5% of cancer-related death in Korea. Consid-
ering the importance of these facts, great emphasis must
be placed on understanding the risk factors for lung cancer.
Though smoking is known as a major risk factor for lung
cancer, IPF and emphysema are also known as independent
risk factors for lung cancer occurrence [8e10]. However,
CPFE as a risk factor for lung cancer is not well understood.
The incidence of lung cancer increased in IPF patients
compared to a normal population [8,20]. Although smoking
is a risk factor for IPF [21] and this might confound an ac-
curate assessment of the impact of IPF on lung cancer, a
previous study showed that IPF was an independent risk
factor for lung cancer development [8]. In addition,
emphysema was a risk factor for lung cancer development.
Like IPF, emphysema is related to smoking [22], and after
adjusting for the confounding effects of smoking, emphy-
sema is an independent risk factor for lung cancer devel-
opment [9]. Furthermore, smoking, which is more strongly
associated with CPFE patients, is the most important risk
factor for lung cancer [12].
Considering these results, we assumed that CPFE, which
has both the features of IPF and emphysema and is pre-
dominant among smokers, might be a higher risk factor for
lung cancer development than IPF and emphysema.
The pathogenesis of lung cancer is not fully understood.
However, repeated lung injury and chronic inflammation
are thought to contribute to the tumorigenesis of lung
cancer in both emphysema and IPF. A previous report sug-
gested that repeated epithelial injury in IPF predisposes for
several genetic mutation, including upregulated p53 and
p21 and these changes lead to lung cancer development
[23]. Like IPF, chronic inflammation and derived genetic
mutations are known to be part of the pathogenesis of lung
cancer in emphysema [24]. However, in addition to chronic
inflammation, different genetic susceptibilities, adaptive
immune responses and hypoxia related angiodysplasia also
Table 3 The risk of lung cancer development in uni- and multivariable analysis.
cHR 95% CI p-Value aHR 95% CI p-Value
CPFE versus emphysema 3.40 1.39e8.32 0.007 4.62 1.58e13.55 0.005
IPF versus emphysema 2.01 0.66e6.20 0.222 4.15 1.03e16.78 0.046
CPFE versus IPF 1.69 0.59e4.81 0.327 1.11 0.38e3.28 0.845
Age 1.05 0.99e1.10 0.084 1.05 0.99e1.11 0.096
BMI 1.07 0.93e1.22 0.340
Number of admission 0.90 0.67e1.22 0.501
Smoking pack-year 1.02 1.00e1.03 0.014 1.02 1.01e1.04 0.005
FEV1 (%) 1.02 1.00e1.04 0.076 1.00 0.98e1.02 0.892
FVC (%) 1.01 0.99e1.03 0.431
FEV1/FVC (%) 1.01 0.99e1.04 0.266
cHR; crude hazard ratio, aHR; adjusted hazard ratio, CI; confidence interval.
528 N. Kwak et al.have a role in the cancer development of emphysema [25].
These differences in tumorigenesis might be related to the
differences in the incidence rate of lung cancer between
IPF and emphysema. Our study showed that the incidence
rate of lung cancer in patients with IPF was higher than that
in patients with emphysema.
We assumed the difference in tumorigenesis might have
an impact on the location of lung cancer in IPF and
emphysema. Lung cancer in IPF is reported to occur in the
peripheral area rather than in the central area. Even
though there is still debate whether the development of
lung cancer has similar features with the development of
fibrotic lesions [26], many studies have shown a peripheral
and lower lobe dominancy in lung cancer development in
IPF [27,28]. However, lung cancer in emphysema is known
to occur frequently in the upper lung [10,29]. Our study
showed a tendency for cancer to occur in the subpleural
area in IPF, but not in emphysema. The occurrence of
subpleural cancer was seen in CPFE. Eight out of twelve
lung cancers in the CPFE patients occurred in <1 cm from
the pleural surface. There is still a lack of information on
the frequency of locations for lung cancer in CPFE. How-
ever, in our study, like lung cancer in IPF, lung cancer in
CPFE occurred more frequently in the subpleural area
compared to lung cancer in emphysema. The tendencyFigure 2 KaplaneMeier estimates of time to lung cancer or
death among patients with CPFE, IPF and emphysema.toward the subpleural location for lung cancer in CPFE
might suggest that emphysema did not have an additive
impact on lung cancer development in CPFE. This assump-
tion could be used to explain why there was no significant
difference in lung cancer risk among the CPFE and IPF
patients.
In addition, there are some other possible explanations
for the fact that there was no significant difference in lung
cancer risk between CPFE and IPF. First, there is the pos-
sibility that the CPFE patients do not have a higher lung
cancer risk than that of patients with IPF only. As a previous
study reported, CPFE could be a distinct disease entity from
IPF and emphysema due to the specific characteristics of
CPFE [2]. In this respect, genetic and environmental factors
that have a predisposition to CPFE could be different from
that of IPF and emphysema. That is, if CPFE was not the
sum of IPF and emphysema, our hypothesis that the lung
cancer risk of CPFE is higher than that of IPF and emphy-
sema might be incorrect. Second, although our study
included a relatively large number of patients for CPFE and
IPF than that of prior studies [5,30], the fact that both CPFE
and IPF are not common diseases and the incidence rate of
lung cancer is also low could lead to a lack of statistical
power. Third, there might be potential bias in the patient
selection. The patients who underwent chest CT scans at
tertiary hospital were enrolled and these patients might
have limitation as the representative of each disease. In
addition, there could be concerns that matching methods
we used in combination with multivariable adjustment to
overcome selection bias [31] might not be the most
appropriate way for analysis. Also, the severity of each
disease was not considered and female patients were
excluded from the analysis in the process of patients
matching. Fourth, a relatively short follow-up duration
could be another limitation. As mentioned earlier, chronic
inflammation and injury have an impact on the pathogen-
esis of lung cancer. In this respect, a longer follow-up
period might be more helpful in detecting cancer devel-
opment. However, in our study, the mean follow-up dura-
tion for all three groups was less than 7 years.
In conclusion, patients with CPFE had a higher risk of
lung cancer development compared with those with
emphysema, although we did not find a statistically signif-
icant difference in lung cancer risk between the CPFE group
and IPF only group.
Table 4 The risk of lung cancer development or death in uni- and multivariable analysis.
cHR 95% CI p-Value aHR 95% CI p-Value
CPFE versus emphysema 3.70 2.03e6.74 <0.001 4.62 2.25e9.47 <0.001
IPF versus emphysema 4.88 2.73e8.74 <0.001 5.28 2.40e11.61 <0.001
CPFE versus IPF 0.76 0.44e1.29 0.310 0.87 0.47e1.2 0.874
Age 1.04 1.01e1.07 0.005 1.04 1.01e1.07 0.018
BMI 1.05 0.97e1.14 0.206
Number of admission 1.08 0.96e1.22 0.209
Smoking pack-year 0.99 0.98e1.00 0.114 1.01 0.99e1.02 0.308
FEV1 (%) 1.00 0.99e1.01 0.423
FVC (%) 0.98 0.97e0.99 <0.001 0.98 0.97e0.99 0.001
FEV1/FVC (%) 1.02 1.01e1.03 0.001 1.00 0.98e1.01 0.601
cHR; crude hazard ratio, aHR; adjusted hazard ratio, CI; confidence interval.
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